欧盟批准的抗癫痫药物Cenobamate（Ontozry? ）为成人难治性局灶性癫痫发作（伴或不伴继发全面性发作）提供了新的辅助治疗方案。临床研究表明，该药物短期使用可显著降低发作频率，50%以上患者实现发作频率减半，且疗效持续长达48个月。低起始剂量（12.5 mg/天 ...

为评估 Cenobamate（CNB）作为超难治性局灶性癫痫附加治疗的长期疗效、耐受性及对联合抗癫痫药物（ASM）的影响，丹麦癫痫中心研究人员开展相关研究。结果显示部分患者有效，且不良反应可调整处理。该研究为 CNB 临床应用提供依据。 癫痫，这个古老而神秘的 ...

Ltd., will present meaningful encore data on XCOPRI ® (cenobamate tablets) CV, an anti-seizure medication, at the 77th American Academy of Neurology (AAN) Annual Meeting, taking place April 5-9 ...

According to a real-world study, cenobamate was effective in patients with drug-resistant epilepsy (DRE), with 49.3% of patients achieved a 50% or greater reduction in seizure frequency at 3 months.

Epilepsy patients and advocates are calling on the Saskatchewan government to provide public coverage for a new anti-seizure ...